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Abstract 
Background and aims: Orthotopic liver transplantation (OLT) can be an effective treatment option for certain 
patients with early stage hepatocellular carcinoma (HCC) meeting Milan, UCSF, or Hangzhou criteria. However, HCC 
recurrence rates post-OLT range from 20 to 40 %, with limited follow-up options. Elucidating genetic drivers common 
to primary and post-OLT recurrent tumors may further our understanding and help identify predictive biomarkers of 
recurrence—both to ultimately help manage clinical decisions for patients undergoing OLT.
Methods: Whole exome and RNA sequencing in matched primary and recurrent tumors, normal adjacent tissues, 
and blood from four Chinese HCC patients was conducted. SiRNA knockdown and both qRT-PCR and Western assays 
were performed on PLCPRF5, SNU449 and HEPG2 cell lines; immunohistochemistry and RNA Sequencing were con-
ducted on the primary tumors of Chinese HCC patients who experienced tumor recurrence post-OLT (n = 9) or did 
not experience tumor recurrence (n = 12).
Results: In three independent HCC studies of patients undergoing transplantation (n = 21) or surgical resection 
(n = 242, n = 44) of primary tumors (total n = 307), HERC5 mRNA under-expression correlated with shorter: time to 
tumor recurrence (p = 0.007 and 0.02) and overall survival (p = 0.0063 and 0.023), even after adjustment for rel-
evant clinical variables. HERC5 loss drives CCL20 mRNA and protein over-expression and associates with regulatory 
T cell infiltration as measured by FOXP3 expression. Further, matched primary and recurrent tumors from the 4 HCC 
patients indicated clonal selection advantage of Wnt signaling activation and CDKN2A inactivation.
Conclusions: HERC5 plays a crucial role in HCC immune evasion and has clinical relevance as a reproducible prog-
nostic marker for risk of tumor recurrence and survival in patients.
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Background
Hepatocellular carcinoma (HCC) is the most common 
primary liver malignancy and third leading cause of 
cancer deaths worldwide, with Hepatitis B virus a major 
etiological factor [1, 2]. Beyond sorafenib (Bayer Health-
Care Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc, 
Germany) which is only effective in a small patient popu-
lation, there is no approved treatment for HCC. Patients 
have limited options, and orthotopic liver transplanta-
tion (OLT) is viable for certain early stage HCC cases, 
though it is only efficacious in a subset meeting Milan, 
Toronto, or UCSF clinical criteria [3–5]. The HCC recur-
rence rates after OLT range from 20 to 40 %, and treat-
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certain clinicopathologic variables such as tumor size 
and absence of macroscopic vascular invasion are used to 
predict risk of recurrence, though success of these factors 
vary from study-to-study [6]. In an effort to improve the 
prediction of HCC recurrence, molecular profiling has 
been applied in many studies.
Multiple transcriptomic and proteomic studies have 
been conducted to help understand the link between 
molecular mediators and factors of etiology, tumo-
rigenesis, disease course, and/or other variables related 
to survival and recurrence in HCC. In fact, from 2003 
to 2010, over 14 studies have identified gene signatures 
from a minimum of 12 genes or proteins to 186, totally 
more than 934 genes for purposes of predicting sur-
vival and/or recurrence in HCC patients [7–21]. More 
recently, Kim et  al., developed a 233 gene signature to 
discern early from late tumor recurrence in primarily 
HBV-positive HCC [22], while Zheng et al., combined a 
122 gene hepatic stellate cell signature with clinical vari-
ables for a prognostic index to predict overall survival in 
HCV-positive cirrhosis or HCC patients [23]. In contrast 
to gene or protein signatures, single analyte prognostic 
gene expression markers such as TNF-related apoptosis-
inducing ligand (TRAIL) mRNA was shown to associ-
ate with tumor growth and survival, though the latter 
result did not show statistical significance, and mela-
noma-associated antigen-D2 (MAGE-D2)  mRNA was 
identified by Hashimoto et al., as a prognostic factor for 
disease-specific survival following curative hepatectomy 
[24, 25] The commonality of genes across these studies 
is low, primarily due to factors of: heterogeneity within 
HCC populations, degraded RNA isolated from forma-
lin-fixed tissues, differences in clinical stages and etiolo-
gies, small sample sizes, lack of independent validation, 
and basic analytical strategy used to identify predic-
tive genes. Beyond gene or protein expression patterns 
shown in these studies, the underlying genetic role in 
HCC recurrence and how it influences pathway modula-
tion has not been explored—something that can greatly 
enhance our ability to accurately predict tumor recur-
rence in HCC.
Recent sequencing studies have advanced our knowl-
edge of genetic oncodrivers in HCC, identifying the 
most recurrent functional impacting mutations in genes 
and frequently modulated pathways such as Wnt signal-
ing, G1/S cell cycle signaling, apoptosis, and JAK/STAT 
signaling [26–29]. Additional work has helped elucidate 
both sites and functional effects of the viral-host genome 
integration for HBV within HCC patients [30, 31]. These 
studies have provided a foundation for the genetic land-
scape of primary tumors in HCC patients though the 
genetic basis leading to tumor recurrence remains 
poorly understood, particularly somatic variation shared 
between the primary and recurring tumors and mecha-
nisms supporting certain predictors of survival or disease 
recurrence, beyond statistical correlates.
In this study, we used an integrated omics strategy to 
identify a hemizygous DNA deletion and concordant 
mRNA under-expression of HERC5, an IFN-induced 
HECT-type E3 protein ligase gene associated with 
shorter: time to tumor recurrence and overall survival 
in HCC patients. The downstream immune-pathological 
impact from loss of HERC5 was also determined. Addi-
tionally, this study indicates a clonal selection advantage 
in the genetic changes in Wnt signaling in the recurrent 
tumors, relative to primary tumors of HCC patients. 
Assessing risk of such outcomes in HCC is a significant 
unmet need and a predictive biomarker to help manage 




To adhere to REporting recommendations for tumour 
MARKer prognostic studies (REMARK) reporting of 
clinical specimens, 21 patients within the Hangzhou 
criteria [4] who underwent OLT at Renji Hospital from 
2008 to 2012 were retrospectively included in this study. 
No stratification or matching was used for patient inclu-
sion in this study. Informed written consent was obtained 
from each patient and the study protocol conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki 
as reflected in a priori approval by the Ethics Committee 
of Renji Hospital. No donor organs were obtained from 
executed prisoners or other institutionalized persons. 
Within 24  months after OLT, 9 patients had recurrent 
liver tumors or remote metastasis following OLT, while 
the remaining 12 patients were tumor free. All clinical 
variables considered are provided in Table 1 and further 
detailed in Additional file 1: Table S1. The primary tumor 
(PT) and normal adjacent tissue (PNAT) were collected 
from all patients (n  =  21). The recurrent tumor (RT), 
normal adjacent tissue from donor (RNAT), and recipient 
blood (PB) were collected from 4 of 9 recurrent patients.
DNA sequence, read mapping and variant calling
DNA exome sequencing (WES) was generated by Bei-
jing Genomics Institute (BGI) using the Illumina stand-
ard library preparation and sequencing protocols [30]. 
Paired-end 90mer sequence FASTQs for both data types 
were provided to MedImmune. WES data was avail-
able from four patients, all of whom experienced tumor 
recurrence post-OLT with the following specimens: PT, 
RT, PNAT, RNAT, and PB. QC and both patient-level and 
summarized variants results are provided in Additional 
file 1: Tables S2–S5. Detailed explanations of somatic and 
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germline variant and indel calling is provided in Addi-
tional file 2, in addition to the following methods: Patient 
identity, Clonal relationship value derivation, Donor tis-
sue presence in recurrent tumors, Somatic copy number 
variation (CNV) analysis, Specificity of HERC5 prog-
nostic correlation among genes in chr4q, and Integrated 
pathway analysis (Additional file 1: Tables S6–S8).
RNASeq read mapping and differential expression analysis
RNASeq data was generated by BGI using the Illumina 
standard library preparation and sequencing protocols 
[30]. Paired end 90mer sequence FASTQs were provided 
to MedImmune. Sequence data was QCd using FastQC 
(v0.10.1), with average read count per mate 50 mil-
lion. Reads were mapped to reference (UCSC hg19; Feb 
2009 release; Genome Reference Consortium GRCh37) 
using TopHat2 (v2.0.9; 32) using the human reference 
gtf annotation file (GRCh37.68). Transcript counts were 
calculated/normalized using htseq-count and DESeq 
(v1.12.1; 33). DESeq’s negative binomial distribution was 
used to calculate p-values and fold changes between PT 
and PNAT as well as RT and RNAT using p < 0.01 and |fold| 
>2 as a threshold for the four patients. These results 
were used in the pathway analyses and combined with 
the same genes harboring copy number (CN) amplified 
or deleted regions (see Additional file  2 for CN calling 
methods). Unadjusted p-values were utilized to simply 
identify the most differential transcripts within a single 
patient (PT vs. PNAT) using the fold change magnitude as 
a primary gene ranking. Since p value calculations were 
conducted within each patient, there was no replica-
tion and statistical power was not adequate to warrant 
multiple testing adjustment. Tumor cell prevalence was 
evaluated using ABSOLUTE [34] and verified against 
pathology assessments for each tumor. RNASeq data 
was available from 21 patients (9 experienced tumor 
recurrence post-OLT and 12 did not) with the following 
specimens: PT and PNAT.
Time-to-event analyses
Time-to-event analyses were used to correlate the expres-
sion of the four genes (NAA11, HERC5, DDX60, and 
HERC6) identified with tumor recurrence among the 21 
Chinese patients’ primary tumors from this study (n = 9 
experienced tumor recurrence; n  =  12 did not experi-
ence tumor recurrence). The expression of each gene 
in the normal adjacent tissue was subtracted from the 
tumor expression for each patient (PT-PNAT) individually, 
then each gene was cut at the median into high or low 
expression groups. In alignment with REMARK criteria, 
Kaplan–Meier (KM) analysis, univariate Cox propor-
tional hazards (PH) regression, and multivariate Cox PH 
regression analyses were conducted adjusting for HBV 
status post-OLT, age (binary), gender, and tumor grade. 
These four variables were the most relevant for potential 
confounding factors with a molecular prognostic. Cir-
rhosis status was positive for all but one patient, so this 
variable was not used in the analysis of these 21 patients. 
HERC5 was the only significant correlate (p < 0.05) with 
tumor recurrence among the four genes using a KM 
model (Fig. 3a; Table 2).
Then, correlation between under-expression of HERC5 
and both progression-free survival (PFS) and overall 
survival was conducted in a publically available HCC 
microarray dataset [35, E-TABM-36]. This HERC5 under-
expression was also tested again with both HCC recur-
rence and overall survival in an additional publically 
available microarray dataset [36, GSE14520]. As was con-
ducted for the 21 HCC patients in this study, the three 
different analysis models (KM model, univariate Cox PH 
regression, and multivariate Cox PH regression) were 
used to test association of HERC5 under-expression with 
outcomes in these additional studies (Table 2). For study 
[36], liver tissue from healthy donors was available, so 
HERC5 (219863_at) was divided into high or low patient 
groups using mean-2 standard deviations (SD) of the nor-
mal liver distribution (n = 239) as the cut point (n = 62 
and 180 HCC patients in low or high groups, respectively 
[18 patients were missing clinical data]). The difference 
between these groups was assessed using the group-
ing coefficient p-value, hazard ratio, and likelihood ratio 
test, in multivariate Cox PH regression with the available 
variables of age, cirrhosis (binary), gender (binary), HBV/
HCV status (active viral replication chronic carrier = 2; 
chronic carrier = 1; no = 0), and TNM staging (I, II, or 
III). The same variables were also assessed individually 
in univariate Cox PH regression. Both overall survival 
and time to tumor recurrence were assessed in two sepa-
rate analyses (Fig. 3b; Table 2). For study [35], no normal 
healthy tissue (matched nor independent subject as in 
study [36]) was available, so HERC5 was cut into high or 
low groups using the median of the HCC primary tumor 
expression values (n =  20 and 24 HCC patients in low 
or high groups, respectively [four patients were missing 
clinical data]). Then overall survival and PFS between 
high and low patient groups was computed adjusting for 
the available variables of gender (binary), age, and HBV 
(titer negative  =  0; titer positive  =  1) status (Fig.  3c; 
Table 2). Note that all available clinical variables in both 
microarray validation studies were analyzed with both 
univariate and multivariate Cox PH regressions with 
HERC5 to assess contribution of these variables to prog-
nostic outcomes. All model summaries are reported in 
Table 2.
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Table 2 Univariate Kaplan–Meier (KM) and  Cox proportional hazards (PH) models and  multivariate Cox PH models 
for the 21 Chinese HCC patients in this study, HCC patients from Roessler et al. study, and HCC patients from Boyault et al. 
study
21 Chinese patients Recurrence (n = 21; 9 events)
HR (95 % CI) p value
Univariate Cox PH
 HBV pre-OLT (Yes, No) 0.285 (0.06, 1.48) 0.14
 Tumor grade (GI, GII GIII) 1.27 (0.63, 2.01) 4.50E−02
 Age (<49) 2.33 (0.62, 8.68) 0.21
 Gender (M, F) 0.29 (0.03, 2.47) 0.26
 HERC5 (Low, High) 10.34 (1.28, 83.55) 0.029
Univariate KM
 HERC5 (Low, High) 0.007
Multivariate Cox PH
 HERC5 (Low) 7.29 0.07
 HBV pre-OLT (Yes, No) 0.26 0.3
 Tumor grade 2.41 0.27
 Age (<49) 2.08 0.42
 Gender (M, F) 1.86 0.7
Roessler et al. study Survival (n = 224; 86 events) Recurrence (n = 224; 125 events)
HR (95 % CI) p value HR (95 % CI) p value
Univariate Cox PH
 HBV (AVR-CC, CC, No) 1.32 (0.86, 2.03) 0.212 1.24 (0.86, 1.79) 0.26
 TNM Staging (I, II, III) 2.34 (1.77, 3.09) 2.18E−09 1.76 (1.41, 2.20) 7.81E−07
 Age (<50) 1.26 (0.84, 1.88) 0.262 1.01 (0.72, 1.42) 0.96
 Gender (M, F) 1.86 (0.09, 3.83) 0.0933 2.36 (1.24, 4.50) 0.009
 Cirrhosis (No, Yes) 0.20 (0.05, 0.80) 0.0227 0.50 (0.23, 1.07) 0.07
 HERC5 (Low, High) 1.79 (1.17, 2.74) 0.00706 1.55 (1.07, 2.24) 0.021
Univariate KM
 HERC5 (Low, High) 0.0063 0.0198
Multivariate Cox PH
 HERC5 (Low) 2.02 0.004 1.8 0.004
 Gender (M, F) 1.36 0.42 2.07 0.03
 Cirrhosis (No, Yes) 0.28 0.076 0.56 0.17
 Age (<50) 1 0.99 1.01 0.49
 HBV (AVR-CC, CC, No) 1.3 0.25 1.36 0.11
 TNM Staging (I, II, III) 2.32 1.06E−08 1.74 2.21E−06
Boyault et al. study Survival (n = 41; 20 events) PFS (n = 41; 20 events)
HR (95 % CI) p value HR (95 % CI) p value
Univariate Cox PH
 HBV (Yes, No) 1.32 (0.51, 3.40) 0.57 1.02 (0.44, 2.38) 0.96
 Gender (M, F) 1.01 (0.34, 3.03) 9.88E−01 1.30 (0.49, 3.41) 6.01E−01
 Age (<65) 1.10 (0.45, 2.67) 0.85 1.48 (0.70, 3.17) 0.31
 HERC5 (Low, High) 2.69 (1.11, 6.51) 0.029 1.96 (0.95, 4.05) 0.07
Univariate KM
 HERC5 (Low, High) 0.023 0.07
Multivariate Cox PH
 HERC5 (Low) 3.31 0.018 3.8 0.01
 HBV (Yes, No) 1.28 0.63 1.16 0.78
Page 6 of 15Xue et al. J Transl Med  (2015) 13:379 
Biological significance of HERC5 loss in HCC
HERC5 siRNA transfection experiments, Microarray 
study of HERC5 siRNA knockdown in HCC cell lines, 
qRT-PCR (TaqMan) Validation, and Cell culture, ELISA 
assays and FOXP3 IHC assay on PT and PNAT samples are 
described in Additional file 2.
Results
Identification of tumor origin and estimation of donor cell 
contamination in the recurrent tumors of HCC patients 
post-OLT
Cases of donor-transmitted malignancies in cadaveric 
organ transplants are very rare [37, 38] in that recurrent 
HCC cases post-OLT are likely tumors derived from the 
recipient, thus the recurrent tumor (RT) genetic com-
position should match the primary tumor (PT). Previ-
ous studies have used microsatellite markers or CNVs to 
answer this question of tumor origin post-OLT or resec-
tion in HCC, as it has important implications for clini-
cal and therapeutic strategies [37–39]. We implemented 
a derivation of the clonal relationship value [CR, 39] 
to determine the tumor origin in the RTs for the four 
patients—all four were of recipient origin (Additional 
file 2, Additional file 3: Figure S5).
Single nucleotide variants (SNVs) were used to assess 
donor tissue contamination within each RT. Since all 
four RTs were determined to originate from the recipi-
ent, any clonality difference between the PTs and RTs, 
such as clonal frequencies is due to purity of the RT 
biopsy [40]. Donor cell contamination in the capture of 
the RT can dilute the magnitude of somatic differences. 
Elimination of recipient versus donor-identified differ-
ences [normal adjacent tissue from donor (RNAT) vs. 
recipient blood (PB)] controls for some of this contami-
nation, though the distribution of cancer clones will still 
vary between the PTs and RTs. The malignancy in patient 
HCC11 occurred in the lung, thus, both primary and 
metastatic tumors were of recipient origin, serving as a 
negative control against the other three patients. Using 
two independent approaches—somatic SNVs or germline 
SNPs, for each patient (Additional file  2), we estimated 
the proportion of donor cell contamination in the RTs as: 
HCC1 =  72–86  %; HCC4 =  3–9  %; HCC5 =  48–64  %; 
and HCC11 = 0 % (recipient = donor; Additional file 3: 
Figure S6A–B).
Somatic single nucleotide variant and insertion/deletion 
identification in primary and recurrent tumors of 4 HCC 
patients
We first asked whether there were potential major 
drivers shared between the PTs and RTs in HCC. Fol-
lowing quality control of the WES and RNASeq data 
(Additional file  3: Figures  S2, S3), we identified 1,145 
somatic variants using a stringent selection approach 
and controlling for donor-recipient differences (i.e. 
elimination of RNAT vs. PB variants; Additional file  2) 
in both PTs and RTs including 616 somatic nonsilent 
(nonsynonymous, stop-gain, stop-loss, or frameshift 
substitution) SNVs or insertion/deletions (indels) 
affecting 567 genes (Additional file  1: Tables  S3–S5). 
On average 123 and 121 nonsilent somatic SNVs and 
5 and 4.3 indels were identified, respectively in the PTs 
and RTs—an average of 96 SNVs and 3.5 indels shared 
between these tumors (Additional file 1: Table S3). The 
somatic SNV distribution in PT and RT specimens had 
highest occurrences of C > T/G > A and lowest occur-
rences of T  >  G/A  >  C (Additional file  3: Figure  S4), 
consistent with a previous HCC report of coding exons 
[27], and PT and RT pairs for each patient had similar 
distributions of transition/transversion substitutions, 
though it is interesting that HCC11 showed highest 
prevalence of T  >  A/A  >  T. The nonsilent-to-silent 
SNV rate was average of 2.8 in the PTs and 2.3 in the 
RTs—a lower ratio in the RTs due to donor-tissue con-
tamination ( Additional file  1: Table  S3, Additional 
file 2). Nonsilent variants shared between PTs and RTs 
had a higher proportion of clones compared to each 
unique set (Additional file 3: Figure S1A-D) and vari-
ant allele frequencies (Vfs) for these shared SNVs were 
significantly higher (mean  =  39.4) than those unique 
to PTs (mean = 23.4; p < 0.001 all four patients; Addi-
tional file  1: Table  S3; Additional file  3: Figure  S1E), 
suggesting shared somatic mutations to likely be driver 
mutations. The SNVs in the PTs called using WES 
Models indicate predictions of survival, PFS, or HCC recurrence with HERC5 mRNA expression and other relevant clinical factors
Tumor grade is defined by American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010; TNM staging levels are defined by 
the TNM combinations corresponding to one of five stages (stages I–V)
AVR-CC active viral replication chronic carrier, CC chronic carrier, No no HBV
Table 2 continued
Boyault et al. study Survival (n = 41; 20 events) PFS (n = 41; 20 events)
HR (95 % CI) p value HR (95 % CI) p value
 Gender (M, F) 1.22 0.74 1.32 0.64
 Age (<65) 1.02 0.42 1.02 0.4
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were confirmed at certain loci with adequate depth 
and quality using WGS and RNASeq data (Additional 
file 1: Table S4).
Somatic copy number variant (CNV) detection in the 
primary, recurrent, and shared tumors of HCC patients
Somatic copy number (CN) amplifications or deletions 
were selected for uniqueness to the PT, RT, or shared 
between the two, all within at least 3 of 4 patients (Fig. 1; 
“Patients and methods”). Among the hemizygous (hemi) 
or homozygous (homo) amplifications identified, those 
that have been observed in a previous study of primary 
tumors in HCC using comparative genomic hybridiza-
tion [39] are indicated by an asterisk (*). Those amplifi-
cations that were common to both the PT and RT in this 
study included: 1q* (hemi in all patients), 6p* (homo in 2 
patients; hemi in 1 patient), 8q* (homo in 1 patient; hemi 
in 2 patients), 17q* (hemi in 3 patients), and 20p* (hemi 
in 3 patients). Common hemi or homo deletions identi-
fied in PT and RT included: 4q* (hemi in 3 patients) and 
17p* (hemi in 3 patients), and amplified regions unique 
to RTs included 17q (hemi in all patients) and 20q (hemi 
in all patients). Thus, the vast majority of somatic CN 
amplifications or deletions were shared between the PT 
and RT, with two short regions having unique CN ampli-
fications in the RT.
An integrated genetics and genomics analysis identifies 
Wnt-signaling pathway activation and tumor suppressor 
gene CDKN2A inactivation shared in both PTs and RTs 
of HCC patients
Using somatic variants, CNVs, and gene expression 
from PTs and RTs (Additional file 3: Figure S7; “Patients 
and methods”), Wnt/β-catenin signaling was identified 
as the most altered pathway in both PTs and RTs across 
all four patients (Additional file  1: Table  S6). Although 
few affected genes were shared between patients, all 
identified genetic changes had the potential to prevent 
ubiquitin-mediated degradation of beta-catenin in the 
cytoplasm, drive activation of beta-catenin in the nucleus 
Fig. 1 Somatic copy number amplifications (red), deletions (green), or neutral (yellow) identified in the primary (inner track) and recurrent (outer 
track) tumors of a HCC1, b HCC4, c HCC5, and d HCC11; e both shared and unique regions of CN amplifications or deletions in 3/4 patients across 
the genome. Color code is as follows: unique to primary tumors (red amplification; blue deletion); unique to recurrent tumors (brown amplification); 
and shared by the primary and recurrent tumors (green amplification; purple deletion)
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(Fig. 2), and subsequent loss of cell-cycle control by inac-
tivation of CDKN2A.
Specifically, deleterious somatic genetic or genomic 
alterations shared between PTs and RTs included: HCC1: 
nonsilent mutations in TP53 and AKT2, with activation 
of upstream gene signatures in CTNB1, E2F1and TCF4 
and suppression of CDKN2A upstream gene signature; 
HCC4: CDH11 and TGFBR3 stop codon mutations, DNA 
Fig. 2 Wnt/β-catenin signaling and directly related pathways affected by genetic-driven and/or gene expression activation or suppression in 
primary and/or recurrent tumors of 4 HCC patients. Determination of this pathway as most activated using genetic and genomic data is described 
in “Patients and methods” while other top ranked pathways are presented in Additional file 1: Table S6. Each of the 4 patients’ primary or recurrent 
tumors are represented as a quadrant on each pathway node
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amplification in POU5F1 and UBD, and DNA deletion in 
GNAO1with activation of E2F1 and TXB2 upstream gene 
signatures and suppression of upstream gene signatures 
CDKN2A and RB1; HCC5: DNA deletion in CDH1 and 
a nonsilent mutation in TP53 with activation of E2F1 
and MYC upstream gene signatures and suppression of 
upstream gene signatures CDKN2A and TP53; HCC11: 
activating mutation S45Y in CTNNB1, a stop codon 
mutation in LRP1, and a nonsilent mutation in the ANK2 
domain of CDKN2A, with DNA amplification in SOX9. 
All four patients converge on shared inactivation of a key 
cell-cycle control tumor suppressor gene CDKN2A in 
PTs and RTs Using the same strategy to identify the most 
enriched pathways unique to RTs in all patients, cell cycle 
signaling was identified (Additional file 1: Table S7).
HERC5 within chromosome 4q somatic CN deletion shows 
mRNA under-expression and predicts risk of survival 
and tumor recurrence in the primary tumors of HCC 
patients
Next we focused on the largest region of somatic CN 
deletion shared in both the PTs and RTs on chromo-
some 4q (~107 Mbp). Genes were evaluated within this 
region to identify a single molecular biomarker to predict 
HCC tumor recurrence and survival. WES and RNASeq 
from the four patients as well as RNASeq from PTs and 
PNATs from a larger population of HCC Chinese patients 
who experienced tumor recurrence (n  =  9 including 
the 4 described above) or did not (n = 12) were used to 
identified a predictor of tumor recurrence and survival. 
Using RNASeq data from the 21 PTs and PNATs, DESeq-
normalized log2 gene counts in the PTs were scaled by 
the matched PNATs within each patient. Then these fold 
changes for each patient were used in a contrast between 
patients that experienced tumor recurrence (n = 9) and 
patients who did not (n = 12). A total of 273 genes were 
identified with |fold|  >2 and p  <  0.01 (Additional file  1: 
Table S9). To provide a large enough set of genes trend-
ing with under-expression in the recurrent patients, no 
multiple testing was implemented on these raw p-values. 
Further, the small sample sizes did not allow multiple 
testing corrections. Then genes within regions of DNA 
deletions in matched PTs and RTs in chromosome 4q (542 
genes) and the 110 genes under-expressed (of the 273 
genes both under- and over-expressed) in the PTs of HCC 
patients who experienced tumor recurrence (n  =  9), 
relative to those who did not (n =  12; Additional file 1: 
Table S9) were intersected. From this analysis, the follow-
ing genes were identified: NAA11, HERC5, DDX60, and 
HERC6 which were evaluated individually for association 
with tumor recurrence using the 21 Chinese patient pri-
mary tumors.
For each of the four genes, the 21 Chinese patients were 
categorized into high/low gene groups using the median 
fold change expression (Fig. 3a). Kaplan–Meier log-rank 
tests indicated a significantly shorter time to recurrence 
in the gene HERC5 low group (p  =  0.007), while the 
other three genes did not significantly correlate with time 
to recurrence (p  >  0.05), and after adjustment for HBV 
status pre-OLT, tumor grade, age, and gender, the trend 
remained for HERC5 (p = 0.07; HR = 7.29 CI95 = [0.85, 
62.62]; Fig. 3a; “Patients and methods”).
Two additional independent HCC datasets including 
primary tumors from patients who underwent resec-
tion were then evaluated [35, 36] where HERC5 expres-
sion was categorized into high/low patient groups 
using healthy control liver tissue [36] or the median 
of the HCC patient distribution (no normal liver tis-
sue was available in this study) [35]. After adjustment 
for cirrhosis status, gender, HBV/HCV status and TNM 
staging, HERC5 was a significant predictor of overall 
survival (p =  0.004; HR =  2.02 CI95 =  [1.26, 3.25]) and 
HCC recurrence (p  =  0.004; HR  =  1.80 CI95  =  [1.20, 
2.69]) in one dataset [36] with median time to recur-
rence in the HERC5 low group  =  23  months versus 
HERC5 high group = 49 months (Fig. 3b; Table 2). Then 
in another independent HCC patient cohort [35], after 
adjustment for age, gender, and HBV status, HERC5 
under-expression was associated with shorter overall 
survival (p  =  0.02; HR  =  3.31 CI95  =  [1.22, 8.96]) and 
PFS (p = 0.01; HR = 3.80 CI95 =  [1.38, 10.43]) (Fig. 3c; 
Table  2). To verify that the lack of correlation between 
the other three candidate genes alternative to HERC5 (i.e. 
NAA11, DDX60, and HERC6) and outcomes was not due 
to the small sample size used in the first patient dataset 
(n = 21), similar analyses were conducted on each gene 
independently using both larger HCC patient cohorts 
[35, 36] and no significant associations were observed 
for any of these three genes with any of the outcomes. An 
additional evaluation of specificity of the HERC5 correla-
tion with prognosis was conducted among all genes that 
were located within the deleted region of chromosome 
4q using study [36] (Additional file  2). A total of 262 
genes were both within the chromosome 4q region and 
present on the microarray from this study, of which 118 
were under-expressed in the HCC tumor biopsies com-
pared to tissue from the normal controls. A multivari-
ate Cox PH model was calculated independently on each 
of the 118 genes, where each gene was cut into high or 
low groups based on the same criteria that was described 
previously (mean-2 SD of the normal liver distribution). 
HAND2 had the most significant association with HCC 
recurrence, although it had a highly unbalanced distri-
bution of high/low patients (3.6 % of patients in the low 
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group). HERC5 was the second most significant correlate 
with HCC recurrence (Additional file 3: Figure S8), dem-
onstrating biological specificity of this gene independent 
of other genes with CN deletions in chromosome 4q.
In a separate study of HCV-positive cirrhosis patients, 
molecular subgroupings of patients were identified and 
shown to correlate with good versus poor prognosis [41]. 
HERC5 was significantly over-expressed (p  <  0.0001) in 
Fig. 3 a left HERC5 distribution of fold change values (log2 scale) for 21 Chinese patient primary tumors, blue line median of patients; right Kaplan–
Meier (KM) curves comparing HERC5 low (n = 11) to high expression (n = 10) predicting recurrence; b left HERC5 distribution between normal liver 
(red; n = 239) and HCC tumors (green; n = 247; 19), blue line mean(normals)-2SD; middle Kaplan–Meier (KM) curves comparing HERC5 low (n = 62) 
to high expression (n = 180) predicting recurrence; right Same as middle predicting overall survival; c left HERC5 distribution for HCC tumors, blue 
line median of 65 patients (20); middle KM curves comparing HERC5 low (n = 20) to high expression (n = 24) predicting PFS; right Same as middle 
predicting overall survival. p log-rank test, p* Cox PH regression model, HR hazard ratio
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the good prognosis (n = 109) compared to poor progno-
sis group (n = 107) (Additional file 3: Figure S9).
HERC5 loss induces CCL20 mRNA and protein 
and associates with FOXP3 positive Treg infiltration in HCC
HERC5 loss was next evaluated for biological significance 
in HCC. By studying the whole transcriptome expres-
sion profile of the HCC cell line PLCPRF5 with HERC5 
siRNA knockdown, CCL20 was the most over-expressed 
transcript (fold =  5.8), and genes coding classic regula-
tors of CCL20 such as TNF, NFKB1, or TRIM32 showed 
no change (Additional file 1: Table S10, Additional file 2). 
TaqMan qRT-PCR and ELISA assays confirmed the over-
expression of CCL20 at the transcript and protein level 
with two additional HCC cell lines (SNU449 and HEPG2; 
Fig. 4). The difference of under-expression in HERC5 in 
the recurrent patient PTs (mean  =  −0.3 fold) was sig-
nificantly lower than that of PTs from patients who did 
not recur (mean =  1.1 fold; p =  0.001), confirming the 
results from the previous two array studies [35, 36] in 
this modest-sized study of Chinese patients. In addition, 
HERC5 and CCL20 mRNAs were significantly negatively 
correlated (p = 0.0003) in the PTs of HCC patients who 
experienced tumor recurrence and not in the PTs of 
HCC patients who did not experience tumor recurrence 
(p = 0.49; Fig. 5a). Immunostaining of FOXP3 in the pri-
mary tumors of the 21 HCC patients indicated signifi-
cantly higher expression in the patients who experienced 
recurrence as compared to those who did not (Fig.  5c; 
p = 0.05).
Discussion
Our results describe the genetic and genomic heteroge-
neity between patients with HCC and demonstrate clonal 
persistence in tumor recurrence post-OLT. A unique 
study design inclusive of PTs and RTs (plus normal adja-
cent tissue and recipient blood), with an integration of 
somatic SNVs, CNVs, and transcript profiling and well-
defined phenotypic spectrum allowed us to elucidate 
key cancer driver genes and delineate those critical gate-
keepers of cancer initiation and progression. This study 
is the first to show a clonal advantage in RTs post-OLT 
compared to PTs in HCC, where Wnt/β-catenin signaling 
activation and tumor suppressor gene CDKN2A inactiva-
tion occurs in both tumors.
DNA CN loss at chromosome 4q was identified as 
one of the only two hemizygous deleted regions shared 
between the primary and recurrent tumors in 3 of 4 Chi-
nese HCC patients. This region accounts for ~107 Mbp 
in length and similar deletions have been associated with 
either poor prognosis or advanced disease stages in pan-
creatic, colorectal, non-small cell lung cancer (NSCLC), 
and HCC tumors [42–46]. Within NSCLC specifically, 
FISH assays identified the primary region of 4q21.2-22.1 
to be associated with poor prognosis [44, 46, 47], and a 
recent study from this same group showed that hyper-
methylation of HERC5 promoter (located at 4q22.1), 
and thus under-expression of the gene correlated with: 
positive disseminated tumor cells in the bone marrow, 
brain metastasis, and poor survival in both stage I ade-
nocarcinoma and metastatic lung cancer patients [46]. 
Our results presented here in primary tumors of HCC 
patients are in agreement with these reports, under-
scoring the prognostic significance of HERC5 under-
expression, as we have demonstrated with microarray or 
RNASeq technologies in primary tumors of three inde-
pendent cohorts of HCC patients.
Cancer cells can avoid an immune response by disa-
bling components of the immune system—a process 
well known as immune evasion. These cells can para-
lyze activated immune effector cells such as infiltrat-
ing cytotoxic T lymphocytes (CTLs) and natural killer 
(NK) cells by secreting TGF-β or other immunosup-
pressive factors [48, 49] such as the cell-cycle control 
tumor suppressor gene CDKN2A. However, the genetic 
basis behind recruitment of inflammatory cells that are 
actively immunosuppressive, such as regulatory T cells 
(Tregs) and myeloid-derived suppressor cells (MDSCs) 
is largely unknown. CCL20 has been shown to be the 
only chemokine significantly up-regulated in HCC tissue 
[50], where it can selectively recruit Tregs to the tumor, 
contributing to an immunosuppressive tumor micro-
environment and leading to poor prognosis in HCC 
[51, 52], Both the genetic basis and mechanism for the 
source of highly secreted CCL20 in HCC still remains 
to be elucidated. Our results suggest that loss of HERC5 
is the genetic precursor for CCL20 over-expression 
and associates with increased Treg infiltration in HCC, 
one of the underlying mechanisms of immune evasion 
in HCC. Further, pathway analysis of the top induced 
genes (|fold|  >2, 129 up-regulated/78 down-regulated) 
following knockdown of HERC5 indicated activation 
of the IL17A pathway, as driven by over-expression of 
chemokine genes CXCL13, CXCL15, and CXCL16, with 
suppression of the Th2 cytokine IL-5, supported by 
the down-regulation of genes TMF1, PDIA6, ELL2 and 
APT1B1. Elevated serum IL17 levels in primary HCC 
patients have been shown to correlate with risk of tumor 
recurrence following curative hepatectomy [53], while 
suppressed IL5 mRNA expression was correlated with 
poor survival in cervical cancer [54]. The modulation 
of such pathways when HERC5 is silenced support an 
immunosuppressed environment for patients, thus influ-
encing poor prognosis. HERC5 is an interferon-induced 
HECT-type E3 protein ligase that mediates type I inter-
feron-induced ISGylation of protein targets; reduction 
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in endogenous HERC5 blocks the IFN-induced ISG15 
conjugation [55]. Thus host anti-viral responses are 
activated by the presence of HERC5 and reduced by its 
absence, suggesting an association with regulation of 
innate immune responses, a potential critical function 
leading to tumor recurrence in HCC. This hypothesis 
requires rigorous evaluation in future studies.
Unlike multiple transcriptomic studies that have devel-
oped gene signatures to predict tumor recurrence or sur-
vival in HCC [7–25], HERC5 was not solely identified as 
a statistical correlate with outcome, rather, this gene is 
located within a large somatic copy number deletion on 
chromosome 4q in both PTs and RTs and was suppressed 
in HCC patients who experienced tumor recurrence, 
Fig. 4 Up-regulated CCL20 expression after HERC5 siRNA knockdown in HCC cell lines. a qRT-PCR analysis of HERC5 mRNA expression in three HCC 
cell lines 96 h after transfection of negative control siRNA and HERC5 siRNA. Shown is relative expression as copy numbers per 106 endogenous 
control genes (average of expression levels of ACTB, GAPDH, and UBC); b qRT-PCR analysis of CCL20 mRNA expression in three HCC cell lines 96 h 
after transfection of negative control siRNA and HERC5 siRNA; c Secreted CCL20 in HCC cell culture medium was measured by ELISA 96 h after siRNA 
transfection. Standard deviations are represented for each bar
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compared to those who did not. Unfortunately in this 
study, HERC5 DNA loss was only evaluated in the 4 HCC 
patients with matched primary and recurrent tumor spec-
imens, since DNA sequencing was not conducted on the 
remaining 17 HCC patients. Although, a recent study of 
185 HCC patients showed that 28 % of patients’ primary 
tumors had a DNA deletion in HERC5, confirming a simi-
lar prevalence to patients with mRNA under-expression in 
this study (26 %; [56]; Additional file 3: Figure S9). Three 
independent studies with available comprehensive clini-
cal and either RNASeq or microarray data were used to 
validate this clinical association totally 307 HCC patients. 
Taken together, these data confirm the robustness of our 
findings. HERC5 is also not present in any gene signature 
among the 14 catalogued in the Liverome database [21].
Studies have shown varied levels of consistency for 
classifying patients with high risk for HCC recur-
rence using clinicopathologic variables such as tumor 
size, vascular invasion, tumor state, tumor grade, and 
alpha-fetoprotein levels and data presented here suggest 
a single transcript as an important variable to couple to 
these relevant clinical factors for identifying HCC candi-
dates for OLT. A single transcript also provides a prag-
matic diagnostic assay for clinical use.
In a disease with no established adjuvant treatments, sub-
stantial shortage of donor organs, and high financial burden, 
identifying eligible patients for OLT with low recurrence 
risk at the molecular level accompanied by current clinical 
criteria, has potential to significantly improve patient clini-
cal outcomes. This study is a first in HCC using compre-
hensive genetics and genomics patient profiling supported 
by large independent patient cohorts to provide evidence 
for such a biomarker and characterize the shared genetic 
drivers between primary and recurrent HCC. We believe 
that the translational study design and analytical strategy 
presented in this work will inspire other genetics studies 
beyond HCC recurrence and into other primary malignan-
cies where metastases to other organs systems are observed.
Fig. 5 Negative correlation between HERC5 and CCL20 mRNA and the association of Tregs infiltration in PTs of recurrent patients. a Log2 fold 
changes HERC5 and CCL20 mRNA between and PNATs in the patients who experienced tumor recurrence (n = 9) or the patients who did not 
(n = 12). A Student’s paired t-test between HERC5 and CCL20 log2 fold change values for the recurrent patients have p = 0.0003 and p = 0.49 for 
the non-recurrent patients. Negative correlation between HERC5 and CCL20 mRNA is present in the recurrent patients and not observed in the 
patients who did not recurrent. b Examples of FOXP3 IHC in PTs and PNATs of a recurrent patient and a non-recurrent patient at ×20 magnifica-
tion (530 × 460 µm in size per field). c FOXP3 IHC scores were calculated using the average numbers of FOXP3 positive stained lymphocytes in10 
randomly selected fields at ×20 magnification (530 × 460 µm in size per field) in hepatocellular carcinoma for each sample. FOXP3 IHC score in PTs 
of recurrent patients (n = 9) were significantly higher than that in non-recurrent patients (n = 9) by Welch’s modified t-test (p = 0.05)
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Conclusion
This study provides evidence for a clonal selection advan-
tage in the recurrent tumor, as compared to primary 
tumor in HCC patients and Wnt/β-catenin signaling was 
identified as the most regulated oncodriver pathway in 
matched primary and recurrent tumors. HERC5 was also 
identified as a prognostic biomarker for both survival and 
tumor recurrence in HCC patients in three independ-
ent HCC patient cohorts. Genetic- and genomic-driven 
under-expression of this gene is associated with CCL20 
induction, suggested to increase Treg infiltration and 
ultimately poor prognosis in HCC patient post-OLT.
Abbreviations
HCC: hepatocellular carcinoma; PT: primary tumor; PNAT: primary normal 
adjacent tissue; PB: recipient blood; RT: recurrent tumor; RNAT: recurrent normal 
adjacent tissue; HBV: hepatitis B virus; HCV: hepatitis C virus; OLT: orthotopic 
liver transplantation; WES: whole exome sequencing; RNASeq: RNA sequenc-
ing; Vf: variant frequency; SNV: single nucleotide variant; indel: insertion or 
deletion; CNV: copy number variation; HR: hazard ratio; CI: confidence interval; 
UCSF: University of California San Francisco; CR: clonal relationship value; WGS: 
whole genome sequencing; Qphred: Phred sequence value score; VCF: variant 
call format; LRR: Log2 R ratios; BAF: B-allele frequency; CTLs: cytotoxic T lym-
phocytes; NK: natural killer; Tregs: regulatory T cells; MDSCs: myeloid-derived 
suppressor cells; HERC5: HECT And RLD Domain Containing E3 Ubiquitin 
Protein Ligase 5; CCL20: chemokine ligand 20.
Authors’ contributions
YY, FX, QX, JG, ZD, YG: study concept and design, acquisition of data, study 
supervision; BWH, JH, CM, WZ, XY, PB, YS, DS, MK: analysis and interpretation 
of data, statistical analysis; BWH, JH: drafting manuscript. All authors read and 
approved the final manuscript.
Author details
1 Department of Liver Surgery and Liver Transplantation, Renji Hospital, 
Shanghai Jiaotong University School of Medicine, Shanghai 201203, China. 
2 Translational Bioinformatics, MedImmune, Gaithersburg, MD 20878, USA. 
3 Asia and Emerging Markets iMed, AstraZeneca R&D, 199 Liangjing Road, 
Shanghai 201203, China. 4 Shanghai Cancer Institute, Renji Hospital, Shanghai 
Jiaotong University School of Medicine, Shanghai 201203, China. 
Competing interests
BWH, JH, CM, WZ, XY, PB, ZX, YS, ZL, DS, MK, ZD, HH, YG, YY: full time employees 
of MedImmune/Astra Zeneca and own stock in Astra Zeneca. FX, YX, JG, QX: 
no conflicts to declare.
Received: 14 June 2015   Accepted: 30 November 2015
References
 1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and 
molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.
 2. Parkin DM. The global health burden of infection-associated cancers in 
the year 2002. Int J Cancer. 2006;118:3030–44.
Additional files
Additional file 1. Supplementary Methods.
Additional file 2. Supplementary Figures.
Additional file 3. Supplementary Tables.
 3. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased 
incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year 
follow-up study. J Natl Cancer Inst. 2009;101:1348–55.
 4. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplanta-
tion for hepatocellular carcinoma: Hangzhou experiences. Transplanta-
tion. 2008;85:1726–32.
 5. Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular 
carcinoma after liver transplantation—an emerging clinical challenge. 
Transpl Int. 2013;26:109–18.
 6. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong 
J, Busuttil RW. Recurrence of hepatocellular carcinoma following liver 
transplantation: a review of preoperative and postoperative prognostic 
indicators. Arch Surg. 2008;143:182–8 (discussion 188).
 7. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, et al. 
Gene expression in fixed tissues and outcome in hepatocellular carci-
noma. N Engl J Med. 2008;359:1995–2004.
 8. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, et al. 
Oligonucleotide microarray for prediction of early intrahepatic recur-
rence of hepatocellular carcinoma after curative resection. Lancet. 
2003;361:923–9.
 9. Iizuka N, Tamesa T, Sakamoto K, Miyamoto T, Hamamoto Y, Oka M. Dif-
ferent molecular pathways determining extrahepatic and intrahepatic 
recurrences of hepatocellular carcinoma. Oncol Rep. 2006;16:1137–42.
 10. Kurokawa Y, Matoba R, Takemasa I, Nagano H, Dono K, Nakamori S, et al. 
Molecular-based prediction of early recurrence in hepatocellular carci-
noma. J Hepatol. 2004;41:284–91.
 11. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, et al. Clas-
sification and prediction of survival in hepatocellular carcinoma by gene 
expression profiling. Hepatology. 2004;40:667–76.
 12. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, et al. Application 
of comparative functional genomics to identify best-fit mouse models to 
study human cancer. Nat Genet. 2004;36:1306–11.
 13. Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, Tamesa T, et al. 
Tumor HLA-DR expression linked to early intrahepatic recurrence of 
hepatocellular carcinoma. Int J Cancer. 2005;115:231–40.
 14. Okamoto M, Utsunomiya T, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki 
T, et al. Specific gene-expression profiles of noncancerous liver tissue 
predict the risk for multicentric occurrence of hepatocellular carcinoma 
in hepatitis C virus-positive patients. Ann Surg Oncol. 2006;13:947–54.
 15. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, et al. Aurora kinase 
B is a predictive factor for the aggressive recurrence of hepatocellular 
carcinoma after curative hepatectomy. Br J Surg. 2008;95:611–9.
 16. Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I. Gene expres-
sion in nontumoral liver tissue and recurrence-free survival in hepatitis C 
virus-positive hepatocellular carcinoma. Mol Cancer. 2010;9:74.
 17. Wang SM, Ooi LL, Hui KM. Identification and validation of a novel gene 
signature associated with the recurrence of human hepatocellular carci-
noma. Clin Cancer Res. 2007;13:6275–83.
 18. Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, et al. Gene expression-
based recurrence prediction of hepatitis B virus-related human hepato-
cellular carcinoma. Clin Cancer Res. 2008;14:2056–64.
 19. Yokoo H, Kondo T, Okano T, Nakanishi K, Sakamoto M, Kosuge T, et al. 
Protein expression associated with early intrahepatic recurrence of hepa-
tocellular carcinoma after curative surgery. Cancer Sci. 2007;98:665–73.
 20. Yoshioka S, Takemasa I, Nagano H, Kittaka N, Noda T, Wada H, et al. 
Molecular prediction of early recurrence after resection of hepatocellular 
carcinoma. Eur J Cancer. 2009;45:881–9.
 21. Lee L, Wang K, Li G, Xie Z, Wang Y, Xu J, et al. Liverome: a curated database 
of liver cancer-related gene signatures with self-contained context infor-
mation. BMC Genomics 2011;12 Suppl 3:S3-2164-12-S3-S3.
 22. Kim JH, Sohn BH, Lee H-S, Kim S-B, Yoo JE, Park Y-Y, et al. Genomic Predic-
tors for recurrence patterns of Hepatocellular Carcinoma: model deriva-
tion and validation. PLoS Med. 2014;11:e1001770.
 23. Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, et al. A 
hepatic stellate cell gene expression signature associated with outcomes 
in hepatitis C cirrhosis and hepatocellular carcinoma after curative resec-
tion. Gut. 2015. doi:10.1136/gutjnl-2015-309655.
 24. Piras-Straub K, Khairzada K, Trippler M, Baba HA, Kaiser GM, Paul A, 
et al. TRAIL expression levels in human hepatocellular carcinoma have 
implications for tumor growth, recurrence and survival. Int J Cancer. 
2015;136:E154–60. doi:10.1002/ijc.29139 (Epub 2014 Aug 23).
Page 15 of 15Xue et al. J Transl Med  (2015) 13:379 
 25. Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, et al. 
Aberrant expression of melanoma-associated antigen-D2 serves as a 
prognostic indicator of hepatocellular carcinoma outcome following 
curative hepatectomy. Oncol Lett. 2015;9:1201–6.
 26. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. 
Whole-genome sequencing of liver cancers identifies etiological influ-
ences on mutation patterns and recurrent mutations in chromatin 
regulators. Nat Genet. 2012;44:760–4.
 27. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, Ishikawa S, et al. High-
resolution characterization of a hepatocellular carcinoma genome. Nat 
Genet. 2011;43:464–9.
 28. Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, et al. Whole-genome 
sequencing identifies recurrent mutations in hepatocellular carcinoma. 
Genome Res. 2013;23:1422–33.
 29. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. Inactivating 
mutations of the chromatin remodeling gene ARID2 in hepatocellular 
carcinoma. Nat Genet. 2011;43:828–9.
 30. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and 
whole-exome sequencing of bladder cancer identifies frequent altera-
tions in genes involved in sister chromatid cohesion and segregation. Nat 
Genet. 2013;45:1459–63.
 31. Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, Guan Y, et al. 
The effects of hepatitis B virus integration into the genomes of hepato-
cellular carcinoma patients. Genome Res. 2012;22:593–601.
 32. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: 
accurate alignment of transcriptomes in the presence of insertions, dele-
tions and gene fusions. Genome Biol. 2013;14(4):R36.
 33. Anders S, Huber W. Differential expression analysis for sequence count 
data. Genome Biol. 2010;11(10):R106.
 34. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. 
Absolute quantification of somatic DNA alterations in human cancer. Nat 
Biotechnol. 2012;30:413–21.
 35. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot 
E, et al. Transcriptome classification of HCC is related to gene alterations 
and to new therapeutic targets. Hepatology. 2007;45:42–52.
 36. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique 
metastasis gene signature enables prediction of tumor relapse in early-
stage hepatocellular carcinoma patients. Cancer Res. 2010;70:10202–12.
 37. Kim B, Woreta T, Chen PH, Limketkai B, Singer A, Dagher N, et al. Donor-
transmitted malignancy in a liver transplant recipient: a case report and 
review of literature. Dig Dis Sci. 2013;58:1185–90.
 38. Cankovic M, Linden MD, Zarbo RJ. Use of microsatellite analysis in detec-
tion of tumor lineage as a cause of death in a liver transplant patient. 
Arch Pathol Lab Med. 2006;130:529–32.
 39. Chen YJ, Yeh SH, Chen JT, et al. Chromosomal changes and clonality 
relationship between primary and recurrent hepatocellular carcinoma. 
Gastroenterology. 2000;119(2):431–40.
 40. Myron KH, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. 
Transplant tumor registry: donor related malignancies. Transplantation. 
2002;74:358–62.
 41. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, et al. 
Prognostic gene expression signature for patients with hepatitis C-related 
early-stage cirrhosis. Gastroenterology. 2013;144:1024–30.
 42. Zhang H, Ma H, Wang Q, Chen M, Weng D, Wang H, et al. Analysis of loss 
of heterozygosity on chromosome 4q in hepatocellular carcinoma using 
high-throughput SNP array. Oncol Rep. 2010;23:445–55.
 43. Danner BC, Gerdes JS, Jung K, Sander B, Enders C, Liersch T, et al. Com-
parison of chromosomal aberrations in primary colorectal carcinomas to 
their pulmonary metastases. Cancer Genet. 2011;204:122–8.
 44. Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmén J, Yekebas EF, et al. Genomic 
profiles associated with early micrometastasis in lung cancer: relevance 
of 4q deletion. Clin Cancer Res. 2009;15:1566–74.
 45. Luebke AM, Baudis M, Matthaei H, Vashist YK, Verde PE, Hosch SB, et al. 
Losses at chromosome 4q are associated with poor survival in operable 
ductal pancreatic adenocarcinoma. Pancreatology. 2012;12:16–22.
 46. Wrage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, Effen-
berger K, et al. Identification of HERC5 and its potential role in NSCLC 
progression. Int J Cancer. 2015;136:2264–72.
 47. Uzunoglu FG, Dethlefsen E, Hanssen A, Wrage M, Deutsch L, Harms-
Effenberger K, et al. Loss of 4q21.23-22.1 is a prognostic marker for 
disease free and overall survival in non-small cell lung cancer. PLoS One. 
2014;9:e113315.
 48. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important 
regulatory axis in the tumor microenvironment and progression. Trends 
Immunol. 2010;31:220–7.
 49. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of 
lymphoidlike stroma and immune escape by tumors that express the 
chemokine CCL21. Science. 2010;328:749–52.
 50. Rubie C, Frick VO, Wagner M, Rau B, Weber C, Kruse B, et al. Enhanced 
expression and clinical significance of CC-chemokine MIP-3 alpha in 
hepatocellular carcinoma. Scand J Immunol. 2006;63:468–77.
 51. Huang F, Geng XP. Chemokines and hepatocellular carcinoma. World J 
Gastroenterol. 2010;16:1832–6.
 52. Ding X, Wang K, Wang H, Zhang G, Liu Y, Yang Q, et al. High expression of 
CCL20 is associated with poor prognosis in patients with hepatocellular 
carcinoma after curative resection. J Gastrointest Surg. 2012;16:828–36.
 53. Wu J, Du J, Liu L, Li Q, Rong W, Wang L, et al. Elevated pretherapy 
serum IL17 in primary hepatocellular carcinoma patients correlate to 
increased risk of early recurrence after curative hepatectomy. PLoS One. 
2012;7:e50035.
 54. Punt S, Houwing JJ, Schulkens IA, Thijssen VL, Osse EM, de Kroon CD, 
et al. A high IL6/IL17 ratio combined with low IL5 expression is correlated 
with poor survival in squamous cervical cancer. J Immunotherap Cancer. 
2014;2:P232. doi:10.1186/2051-1426-2-S3-P232.
 55. Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type 
E3 protein ligase that mediates type I IFN-induced ISGylation of protein 
targets. Proc Natl Acad Sci USA. 2006;103:10735–40.
 56. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, 
et al. Integrated analysis of somatic mutations and focal copy-number 
changes identifies key genes and pathways in hepatocellular carcinoma. 
Nat Genet. 2012;44:694–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
